{"analyses":[{"ciLowerLimit":"-443.79","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"3618.31","groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0985","paramType":"Difference in LS Mean","paramValue":"1587.26","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-2169.67","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1972.58","groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.5315","paramType":"Difference in LS Mean","paramValue":"-98.54","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"84.51","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"4321.85","groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0437","paramType":"Difference in LS Mean","paramValue":"2203.18","statisticalMethod":"MMRM analysis; 1-sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3450.37","upperLimit":"-387.68","value":"-1919.02"},{"groupId":"OG001","lowerLimit":"-1679.81","upperLimit":"1016.29","value":"-331.76"},{"groupId":"OG002","lowerLimit":"-3387.48","upperLimit":"-647.65","value":"-2017.57"},{"groupId":"OG003","lowerLimit":"-1175.46","upperLimit":"1743.77","value":"284.15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"13"}],"units":"Participants"}],"description":"Total vector magnitude is a measure of overall physical activity. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using MMRM model.","dispersionType":"90% Confidence Interval","groups":[{"description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses).","id":"OG000","title":"Part A: Placebo"},{"description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG001","title":"Part A: Ponsegromab 100 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG002","title":"Part A: Ponsegromab 200 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG003","title":"Part A: Ponsegromab 400 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Censored analysis set: all evaluable participants. For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed''=participants evaluable for this outcome measure at Week 12","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12","title":"Part A: Change From Baseline in Total Vector Magnitude at Week 12","type":"SECONDARY","unitOfMeasure":"Total activity counts/100 per day"}